Paul K. Paik

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Resistance to Immune Checkpoint Inhibitor Treatment in Non–Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators

  Journal of Clinical Oncology · 2026-06-03

• Indirect comparison of the effectiveness of tepotinib and immunotherapy in NSCLC with METex14 skipping alterations: Final propensity-scored analysis of eight pooled real-world datasets (TOGETHER) vs the VISION trial.

  Journal of Clinical Oncology · 2026-05-28

• Petosemtamab plus pembrolizumab as first-line (1L) treatment of PD-L1 high metastatic non-small cell lung cancer (NSCLC): Global phase 2 trial.

  Journal of Clinical Oncology · 2026-05-28

• Profiling patients with <i>MET</i> exon 14 ( <i>MET</i> ex14) skipping NSCLC with a sustained clinical benefit to tepotinib in VISION.

  Journal of Clinical Oncology · 2026-05-28

• PP01.28: Treatment Sequencing of Tepotinib in Patients With MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Outcomes From ≥3 Years Follow-Up of the VISION Study

  Journal of Thoracic Oncology · 2026-05-01

• PP01.29: Long-Term Outcomes with Tepotinib for Clinically Relevant Subgroups of Patients with MET Exon 14 (METex14) Skipping NSCLC in the VISION Study: A ≥3-Year Follow-Up

  Journal of Thoracic Oncology · 2026-05-01

• PP01.27: Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) From the VISION Study: ≥3-Year Follow-Up Outcomes

  Journal of Thoracic Oncology · 2026-05-01

• PP01.23: Safety and Patient-Reported Outcomes with Tepotinib in Patients with METex14 Skipping NSCLC: ≥3-Years Follow-Up of VISION

  Journal of Thoracic Oncology · 2026-05-01

• Health-Related Quality of Life (HRQoL) with Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) with Brain, Liver, Adrenal, or Bone Metastases in the Phase II VISION Trial

  Indian Journal of Medical and Paediatric Oncology · 2026-02-01

• Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry

  JCO Precision Oncology · 2025-12-01

• Supplemental Figure 4 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Lung Adenocarcinomas

  2025-11-25

• Supplementary Table 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Lung Adenocarcinomas

  2025-11-25

• Supplemental Figure 1 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Lung Adenocarcinomas

  2025-11-25

• Supplemental Figure 2 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Lung Adenocarcinomas

  2025-11-25

• Supplemental Figure 3 from Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Lung Adenocarcinomas

  2025-11-25

• Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

  Nature Medicine · 2025-11-20

• Supplementary Figure 1 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors

  2025-11-14

• Supplementary Table 3 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors

  2025-11-14

• Supplementary Figure 2 from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors

  2025-11-14

• Data from Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors

  2025-11-14